Navigation Links
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology
Date:2/4/2008

lop innovative improved products to meet the needs of interventional cardiologists and their patients," said Richard L. Klein, president of Medlogics. "Cardiovascular disease remains the nation's greatest killer, and we are committed to providing new technologies that can improve quality of life for these patients."

"Licensing our proprietary biopolymer stent coating technology to Medlogics with their best-in-class stent design allows CV Therapeutics to potentially generate revenues from future milestones and product sales and to continue focusing on maximizing the potential for Ranexa, regadenoson and our pipeline of pharmaceutical therapies," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

About Medlogics

Founded in August 2002, Medlogics is a California corporation based in Santa Rosa, California. Medlogics has vertically integrated drug eluting coating, stent and catheter research, de
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 ... that uses next generation sequencing technology to empower cancer ... Storrer as chief executive officer. In his expanded ... responsible for all strategy, business expansion and worldwide operations ... served as Strand,s chairman and CEO since its founding ...
(Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business ... to lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s ... cash prizes of US$15,000 and a period of expert mentorship from a senior industry ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... DIEGO , March 16  Neurocrine Biosciences, Inc. (Nasdaq: ... recently completed public offering of common stock has exercised in ... common stock to cover over-allotments.  The sale of the additional ... into account the sale of the additional shares at a ...
... Shire plc (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice Letter,from Teva Pharmaceuticals USA, Inc. ("Teva") advising of ... release tablets,INTUNIV(TM). , ... , ... ...
... LONDON, ON , March 16 /PRNewswire/ ... protein therapeutic, demonstrated positive results in a pivotal proof ... model for arthritis. VT-346 achieved a statistically significant, dose ... prevented deterioration due to disease in terms of weight ...
Cached Biology Technology:Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 2Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 2Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 3Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 4
(Date:6/26/2015)... June 26, 2015 ATL Technology, LLC, a top ... specialties in single use solutions, headquartered in Springville, ... (a California corporation with locations in ... San Jose, Costa Rica ). This acquisition ... with ATL Technology,s existing facility in ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Oslo, April 7, 2010: OptiNose, a leader in ... publication in Cephalalgia of results from its ... of its novel, intranasal drug/device product for the treatment ... and 20mg doses administered intranasally using OptiNose,s bi-directional delivery ...
... to exercise, help may be on the way. That,s ... as exercise, promotes new bone growth. This opens the ... into thinking they are getting a workout. The research ... FASEB Journal ( http://www.fasebj.org ). This ...
... Calif.) African-American women have poorer survival rates ... whether they receive radiation therapy following lumpectomy or ... Martinez, assistant professor of surgery at UC Davis ... women with advanced breast cancer are less likely ...
Cached Biology News:OptiNose's novel intranasal sumatriptan product highly effective in treating migraines 2For osteoporosis patients, exercise pill one step closer to reality 2Disparities persist in outcomes for African-American women with advanced breast cancer 2
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... has been designed and created in order ... friendly genotyping analysis tool. We incorporated the ... into the software. Their main requirements were ... low acquisition cost. GeneMarker can perform ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
... 3D structure visualization, phylogenetic tree building, sequence ... single application. Retrieve ... and filter them in real-time Organize ... searching, filtering and sorting Provides up-to-date ...
Biology Products: